Patent · US Active

Method of treating diseases that respond to therapy by dopamine or dopamine agonists

US9108900B2 · kind B2 · utility

2Cited by

12References

10Claims

0Family size

Assignee

UCB Pharma GMBH · DE

Inventors

Dieter Scheller · Brussels, BE
Klaus Hansen · Grevenbroich, DE

Key dates

Filing date	Oct 25, 2013
Grant date	Aug 18, 2015
Priority date	—
Expiry date	Feb 12, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a medicament containing (S)-2-N-propylamino-5-hydroxytetralin, the salts or prodrugs thereof. As a D3 agonist, (S)-2-N-propylamino-5-hydroxytetralin is suitable particularly for the treatment of dopa-sensitive movement disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.